Worldwide, surgical treatment of gastric adenocarcinoma consists of resection of the stomach combined with a lymphadenectomy to remove both macro- and micrometastases of the tumor.[@CR1] In the past, several studies have compared a D1 lymphadenectomy, including perigastric lymph nodes, with a D2 lymphadenectomy, including both perigastric lymph nodes and locoregional lymph nodes. These studies found a survival benefit of D2 lymphadenectomy over D1 lymphadenectomy.[@CR2],[@CR3] As a result, international guidelines recommend D2 lymphadenectomy for all advanced-stage tumors (cT2-4 or cN+).[@CR4],[@CR5]

Elderly patients undergoing major cancer surgery are prone to postoperative morbidity and mortality due to pre-existent comorbidities.[@CR6] Additionally, in some studies a more extensive lymphadenectomy has been associated with higher postoperative morbidity and mortality.[@CR7],[@CR8] These short-term outcomes may be more relevant in elderly patients as the expected survival benefit from an extensive lymphadenectomy is lower compared with younger patients. As elderly patients form a substantial portion of the patients undergoing gastrectomy for cancer,[@CR9] the extent of lymphadenectomy in the elderly is currently under debate.

Lymph node yield (LNY) has frequently been used as a surrogate for the extent of lymphadenectomy.[@CR10] Therefore, the current study aimed to evaluate the influence of LNY on postoperative mortality and overall survival in both young and elderly patients with gastric cancer.

Materials and Methods {#Sec2}
=====================

Study Design {#Sec3}
------------

This population-based observational cohort study included data from The Netherlands Cancer Registry (NCR), which has an area comprising nearly 17 million inhabitants. In The Netherlands, all newly diagnosed cancers are registered in the NCR, which is maintained by the Netherlands Comprehensive Cancer Organisation (IKNL). The National Automated Pathology Archive (PALGA) and the National Registry of Hospital Discharge Diagnoses are important sources for the NCR. Trained data managers register data from hospital records within all Dutch hospitals on a daily basis using the NCR's registration and coding manual, and survival status is updated yearly from the civil registry. The NCR's privacy committee approved this study.

Patients {#Sec4}
--------

In this study, data from patients who underwent a curative gastrectomy for gastric adenocarcinoma (pT0-4a, N0-3, M0) during the period 2006--2014 were selected from the NCR. Patients who underwent multi-organ surgery and patients without follow-up were excluded. Data on patient and treatment-related characteristics, histopathological characteristics, and follow-up were extracted from the NCR, whereas data regarding patients' comorbidities and postoperative morbidity were not available from the NCR.

Diagnosis, Treatment, and Follow-Up {#Sec5}
-----------------------------------

Patients were diagnosed and treated according to the Dutch national guidelines for the diagnosis, treatment, follow-up, and guidance of patients with gastric cancer.[@CR11] The diagnostic work-up consisted of endoscopy with tumor biopsy and computed tomography (CT). In most cases, patients who underwent neoadjuvant chemotherapy received a regimen comparable to epirubicin, cisplatin, and capecitabine.[@CR12] Since 2010, gastric surgery has been centralized in The Netherlands, aiming for a minimum of 20 procedures per center per year.[@CR13] Surgery consisted of a subtotal or total gastrectomy, depending on the possibility of achieving a proximal resection margin of ≥6 cm.[@CR11] In all patients, national guidelines recommended a D2 lymphadenectomy without station 10 dissection, pancreatectomy, and splenectomy, but the NCR did not include information on the actual lymphadenectomy performed. Resection specimens were reviewed by pathologists in accordance with the Union for International Cancer Control (UICC) TNM staging system.[@CR14] Tumors that were staged according to the 6th edition were translated to the 7th edition.[@CR5] The routine follow-up of patients consisted of medical history and physical examination at the outpatient clinic after 6 weeks, 6 months, 12 months, and yearly thereafter until discharge of follow-up after 5 years. Radiological imaging was not routinely performed during follow-up.

Outcome Measures {#Sec6}
----------------

All included patients were divided into two groups based on age according to a previous study;[@CR10] patients younger than 75 years (\<75 years group, young) and patients aged 75 years or older (≥75 years group, elderly). The LNY was categorized into three groups according to a previous study:[@CR10] low (\<15 nodes), intermediate (15--25 nodes), and high (\>25 nodes) LNY. (Sub) acute surgery was defined as surgery within \<7 days after diagnosis, and postoperative mortality was analyzed within 30- and 90-days after surgery. Overall survival was calculated in months from the day of surgery until death or the end of follow-up on 31 December 2015.

Statistical Analyses {#Sec7}
--------------------

To assess the distribution of all baseline, surgical, and histopathological characteristics, a comparison was made between the three groups of LNYs (\<15, 15--25, and \>25 nodes). Categorical variables were analyzed using the *χ* ^2^ test and continuous variables were compared using one-way analysis of variance (ANOVA). To evaluate the influence of LNY on postoperative mortality, univariable and multivariable logistic regression analysis was performed, providing odds ratios (ORs) with 95% confidence intervals (CIs). In addition, the influence of LNY on overall survival was evaluated using univariable and multivariable Cox proportional hazards models, providing hazard ratios (HRs) along with 95% CIs. For the multivariable Cox analysis, a nonparsimonious approach was used for the selection of model variables, including all patient- and treatment-related characteristics, as well as LNY. LNY was included as both a categorical variable and a discrete variable. Results were stratified according to age (\<75 and ≥75 years), and a subgroup analysis was performed based on the radicality of the resection (R0/R+). For all Cox proportional hazard models, nonviolation of the proportional hazards assumption was verified with log-minus-log plots. Adjusted survival curves were made from the proportional hazards models.

Results {#Sec8}
=======

Study Population {#Sec9}
----------------

The NCR selected data from 3814 patients who underwent a curative gastrectomy for gastric adenocarcinoma; a total of 50 patients were excluded as a result of multi-organ surgery (*n* = 45) or lack of follow-up (*n* = 5). Of the remaining 3764 patients, 2387 (63%) were younger than 75 years of age and 1377 (37%) were aged 75 years or older. Patient and treatment-related characteristics and their comparison between young and elderly patients are presented in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of 3764 patients who underwent gastrectomy with curative intent for cancer, stratified by age (\<75 and ≥75 years)AllYoung (\<75 years)Elderly (≥75 years)*p* value*n* = 3764(%)*n* = 2387(%)*n* = 1377(%)Age, years (mean \[SD\])68.7\[±11.8\]62.3\[9.9\]80.0\[3.8\]**\<0.001**Sex0.058 Male2305(61)1489(62)816(59) Female1459(39)898(38)561(41)Malignancy history**\<0.001** No3265(87)2140(90)252(18) Yes499(13)247(10)1125(82)Referral for gastrectomy**\<0.001** No2720(80)1647(77)1073(86) Yes659(20)481(23)178(14) Unknown385259126Year of diagnosis**\<0.001** 2006--20081317(35)807(34)510(37) 2009--20111229(33)747(31)482(35) 2012--20141218(32)833(35)385(28)Neoadjuvant treatment**\<0.001** None2169(58)967(41)1202(87) Chemotherapy1567(42)1400(59)167(12) Radiotherapy4(0.1)0(0)4(0.3) Chemoradiation24(0.6)20(0.8)4(0.3)Surgical urgency**0.014** (Sub)acute157(4)85(4)72(5) Elective3607(96)2302(96)1305(95)Surgical type**\<0.001** Subtotal gastrectomy2438(65)1438(60)1000(73) Total gastrectomy1326(35)949(40)377(27)Surgical approach**0.032** Open3377(91)2120(90)1238(92) Laparoscopic347(9)238(10)109(8) Unknown402930Radicality0.948 R03164(87)2006(87)1158(87) R+461(13)293(13)168(13) Rx1398851(y)pT stage**\<0.001** T0118(3)102(4)16(1) T1720(19)470(20)250(18) T2637(17)386(16)251(18) T31434(39)900(38)534(39) T4a811(22)494(21)317(23) Tx44359(y)pN stage0.729 N01856(49)1173(49)683(50) N1689(18)440(18)249(18) N2604(16)389(16)215(16) N3615(16)395(16)230(17)Tumor differentiation**\<0.001** Well100(4)53(3)47(4) Moderate722(27)366(23)356(32) Poor1886(70)1165(74)721(64) Undifferentiated1(\<0.1)1(\<0.1)0(0) Unknown1055802253Adjuvant therapy**\<0.001** No2736(73)1433(60)1303(95) Chemotherapy790(21)740(31)50(4) Chemoradiation238(6)214(9)24(2)Bold values indicate significance (*p* \< 0.05). Values were rounded to the nearest percentage point*SD* standard deviation

Lymph Node Yield {#Sec10}
----------------

In young patients, the median LNY was 14 (interquartile range \[IQR\] 8--22), compared with 11 (IQR 6--18) in elderly patients (*p* \< 0.001). In the elderly patients, 851 (62%) had a low LNY, 333 (24%) had an intermediate LNY, and 174 (13%) had a high LNY; no data on LNY were available for 19 (1%) patients. In the young patients, 1180 (49%) had a low LNY, 707 (30%) had an intermediate LNY, and 462 (19%) had a high LNY; no data were available for 38 (2%) patients. Comparison of patient- and treatment-related characteristics between the different LNY groups are presented in Table [2](#Tab2){ref-type="table"}.Table 2Baseline characteristics regarding the extent of lymph node yield stratified for age (\<75 years and ≥75 years)Young (\<75 years)Elderly (≥75 years)\<15 nodes15--25 nodes\>25 nodes\<15 nodes15--25 nodes\>25 nodes*n* = 118)(%)*n* = 707(%)*n* = 462(%)*p* value*n* = 851(%)*n* = 333(%)*n* = 174(%)*p* valueAge, years (mean \[SD\])62.9\[± 9.6\]61.8\[± 10.3\]61.3\[± 10.0\]**0.004**80.2\[± 3.8\]79.8\[± 3.7\]79.5\[± 3.2\]**0.041**Sex0.254**0.017** Male744(63)449(64)273(59)524(62)194(58)87(50) Female436(37)258(36)189(41)327(38)139(42)87(50)Malignancy history0.0810.340 No1042(88)643(91)422(91)686(81)275(83)148(85) Yes138(12)64(9)40(9)165(14)58(17)26(15)Referral for gastrectomy**\<0.001\<0.001** No977(86)422(71)217(60)736(91)224(79)94(67) Yes154(14)176(29)144(40)73(9)59(21)46(33) Unknown49109101425034Year of diagnosis**\<0.001\<0.001** 2006--2008525(44)181(26)68(15)387(45)85(26)20(12) 2009--2011408(35)211(30)124(27)313(37)115(34)53(30) 2012--2014247(21)315(45)270(58)151(18)133(40)101(58)Neoadjuvant treatment**\<0.0010.008** None581(49)234(33)130(28)764(90)278(83)142(82) Chemotherapy591(50)465(66)329(71)82(10)52(16)32(18) Radiotherapy0(1)0(1)0(1)2(0.2)2(0.6)0(0) Chemoradiation8833(0.4)1(0.3)0(0)Surgical urgency**0.001**0.095 (Sub)acute56(5)19(3)6(1)52(6)15(5)4(3) Elective1124(95)688(97)456(99)799(94)318(95)170(97)Surgical type**\<0.0010.001** Subtotal gastrectomy817(69)375(53)226(49)647(76)223(67)115(66) Total gastrectomy363(31)332(47)236(51)204(24)110(33)59(33)Surgical approach**\<0.001\<0.001** Open1110(95)599(86)373(83)795(95)295(89)138(81) Laparoscopic58(5)101(14)79(18)41(5)36(11)32(19) Unknown127101524Radicality0.6280.076 R0996(88)592(87)392(88)716(88)274(84)153(90) R+138(12)92(13)52(12)97(12)53(16)17(10) Rx4623183864(y)pT stage**0.026\<0.001** T047(4)34(5)18(4)8(1)7(2)1(0.6) T1265(23)124(18)77(17)194(23)29(9)24(14) T2198(17)118(17)63(14)163(19)58(18)24(14) T3423(36)264(38)201(44)306(36)138(42)83(48) T4a232(20)151(22)100(22)173(21)99(30)42(24) Tx15163720(y)pN stage**\<0.001\<0.001** N0643(54)324(46)183(40)475(56)117(35)82(47) N1247(21)117(17)70(15)162(19)64(19)18(10) N2211(18)100(14)70(15)144(17)46(14)21(12) N379(7)166(23)139(30)70(8)106(32)51(31)Tumor differentiation**\<0.001**0.145 Well35(4)8(2)9(3)35(5)9(3)3(2) Moderate217(27)98(21)48(16)230(33)83(29)38(28) Poor548(68)356(77)251(81)423(62)193(68)93(69) Undifferentiated1(0.1)0(0)0(0)0(0)0(0)0(0) Unknown3792451541634840Adjuvant therapy**\<0.001**0.172 No784(66)387(55)235(51)812(95)308(92)164(94) Chemotherapy314(27)245(35)171(37)29(3)16(5)5(3) Chemoradiation82(7)75(11)56(12)10(1)9(3)5(3)Bold values indicate significance (*p* \< 0.05). Values were rounded to the nearest percentage point*SD* standard deviation

Postoperative Mortality {#Sec11}
-----------------------

The 30- and 90-day mortality in the total study population was 5 and 8%, respectively, and both the 30- and 90-day mortality rates were higher in elderly patients compared with young patients (30-day mortality 10 vs. 3%, *p* \< 0.001; 90-day mortality 14 vs. 5%, *p* \< 0.001, respectively). In elderly patients, the 30-day mortality within the low (\<15), intermediate (15--25), and high (\>25) LNY groups was 10, 10, and 8%, respectively, whereas the 90-day mortality was 15, 14, and 10%, respectively. Multivariable analysis did not demonstrate an association between LNY and postoperative mortality for both young and elderly patients (*p* \> 0.25) (Table [3](#Tab3){ref-type="table"}).Table 3Univariable and multivariable logistic regression analyses on the influence of lymph node retrieval on 30-and 90-day mortality in patients treated with gastrectomy for cancer, stratified for age (\<75years and ≥75 years)Young (\<75 years)30-day mortality90-day mortalityUnivariableMultivariable^a^UnivariableMultivariable^a^OR95% CI*p* valueOR95% CI*p* valueOR95% CI*p* valueOR95% CI*p* valueEach additional node0.990.97--1.020.4450.990.96--1.020.5210.990.97--1.010.1830.990.96--1.010.298\<15 nodesRef--**--**Ref----Ref----Ref----15--25 nodes0.720.40--1.300.2690.650.32--1.320.2360.710.45--1.110.1340.810.47--1.370.429\>25 nodes0.820.43--1.590.5650.850.36--1.990.7010.740.44--1.240.2500.740.37--1.480.400Elderly (≥75 years)30-day mortality90-day mortalityUnivariableMultivariable^a^UnivariableMultivariable^a^OR95% CI*p* valueOR95% CI*p* valueOR95% CI*p* valueOR95% CI*p* valueEach additional node0.990.97--1.010.1731.000.98--1.030.9400.990.97--1.010.1730.990.97--1.020.573\<15 nodesRef----Ref----Ref----Ref----15--25 nodes0.850.59--1.220.3670.940.56--1.580.8230.850.59--1.220.3670.870.55--1.360.538\>25 nodes0.660.38--1.140.1320.740.34--1.600.4420.660.38--1.140.1320.630.32--1.230.178^a^Adjusted for age, sex, malignancy history, referral, year of diagnosis, tumor differentiation, neoadjuvant therapy, surgical urgency, type of surgery, surgical approach, radicality, (y)pT stage, and (y)pN stage*OR* odds ratio, *CI* confidence interval

Overall Survival {#Sec12}
----------------

The median overall survival of all patients was 41 months; 58 months in young patients compared with 27 months in elderly patients. The median survival of elderly patients in the low (\<15), intermediate (15--25), and high (\>25) LNY groups was 26, 26, and 31 months, respectively (*p* = 0.228), whereas the median survival of young patients was 61, 58, and 52 months, respectively (*p* = 0.482). In multivariable analysis, a higher LNY in elderly patients was significantly associated with a prolonged survival when analyzed as a discrete variable (each additional node: HR 0.98, 95% CI 0.97--0.99, *p* \< 0.001) or a categorical variable (\<15 nodes: reference; 15--25 nodes: HR 0.74, 95% CI 0.62--0.88, *p* \< 0.001; \>25 nodes: HR 0.59, 95% CI 0.45--0.78, *p* \< 0.001). These results were comparable for young patients (Table [4](#Tab4){ref-type="table"}). Figure [1](#Fig1){ref-type="fig"} shows the adjusted survival curves of elderly and young patients, stratified by LNY. Subgroup analysis demonstrated that R status did not influence the association between LNY and overall survival (data not shown).Table 4Univariable and multivariable Cox regression analyses on the influence of lymph node retrieval on overall survival in patients treated with gastrectomy for cancer, stratified for age (\<75 years and ≥75 years)Young (\<75 years)Elderly (≥75 years)UnivariableMultivariable^a^UnivariableMultivariable^a^HR95% CI*p* valueHR95% CI*p* valueHR95% CI*p* valueHR95% CI*p* valueLymph node yield \<15 nodesRef--**--**Ref--**--**Ref--**--**Ref--**--** 15--25 nodes0.970.85--1.110.680.710.60--0.83**\<0.001**1.030.88--1.210.690.750.63--0.89**0.001** \>25 nodes1.070.91--1.260.410.620.51--0.76**\<0.001**0.830.67--1.040.100.610.47--0.80**\<0.001**Additional year of age1.011.00--1.02**0.001**1.011.00--1.02**0.008**1.041.03--1.06**\<0.001**1.031.02--1.05**\<0.001**Sex MaleRef--**--**Ref--**--**Ref--**--**Ref--**--** Female1.0010.89--1.130.9821.070.94--1.220.3250.910.80--1.040.1800.800.69--0.92**0.002**Malignancy history No history of malignancyRef--**--**Ref--**--**Ref--**--**Ref--**--** Malignancy in history1.211.01--1.45**0.043**1.200.98--1.460.0761.211.03--1.42**0.021**1.381.15--1.64**\<0.001**Referral Same hospitalRef--**--**Ref--**--**Ref--**--**Ref--**--** Other hospital0.980.85--1.140.8120.990.83--1.170.8591.040.85--1.260.7301.230.99--1.540.064Additional year of diagnosis1.000.97--1.020.7901.061.02--1.09**0.002**0.960.93--0.99**0.003**0.980.95--1.020.360Tumor differentiation WellRef--**--**Ref--**--**Ref--**--**Ref--**--** Moderate1.881.12--3.13**0.016**0.970.57--1.650.8971.070.72--0.600.7390.840.55--1.280.415 Poor2.311.41--3.80**0.001**0.950.56--1.590.8311.731.18--2.55**0.006**1.070.71--1.610.756 Undifferentiated3.950.52--29.80.1820.870.51--1.480.608NANANANANANANeoadjuvant therapy NoneRef--**--**Ref--**--**Ref--**--**Ref--**--** Chemotherapy0.830.74--0.93**0.001**1.100.93--1.290.2640.630.50--0.79**\<0.001**0.940.69--1.270.682 Chemoradiotherapy0.780.39--1.570.4850.420.14--1.320.1392.490.93--6.650.0702.920.91--1.460.072Surgical urgency ElectiveRef--**--**Ref--**--**Ref--**--**Ref--**--** (Sub)acute1.441.09--1.90**0.011**1.160.85--1.580.3421.220.92--1.600.1681.110.82--1.500.501Type of surgery PartialRef--**--**Ref--**--**Ref--**--**Ref--**--** Total1.411.26--1.59**\<0.001**1.271.11--1.45**\<0.001**1.291.12--1.49**\<0.001**1.251.07--1.46**0.005**Surgical approach OpenRef--**--**Ref--**--**Ref--**--**Ref--**--** Minimally invasive0.930.73--1.180.540.980.72--1.330.9010.880.65--1.180.3910.960.64--1.450.849Radicality R0Ref--**--**Ref--**--**Ref--**--**Ref--**--** R13.182.74--3.70**\<0.001**1.651.39--1.96**\<0.001**2.381.99--2.84**\<0.001**0.451.18--1.77**\<0.001** R26.604.13--10.5**\<0.001**1.951.11--3.45**0.021**3.982.24--7.05**\<0.001**2.321.20--4.48**0.012**(y)pT stage T0Ref--**--**Ref--**--**Ref--**--**Ref--**--** T11.170.67--2.060.5791.070.57--2.020.8391.220.50--3.000.6550.910.32--2.600.854 T22.451.42--4.25**0.001**1.801.97--3.360.0641.630.67--3.970.2581.090.38--3.100.872 T35.343.14--9.08**\<0.001**3.201.74--5.87**\<0.001**3.031.25--7.32**0.014**1.570.56--4.430.396 T4a7.654.48--13.0**\<0.001**3.681.96--6.81**\<0.001**4.191.73--10.1**0.002**1.850.65--5.260.249(y)pN stage N0Ref--**--**Ref--**--**Ref--**--**Ref--**--** N12.291.94--2.69**\<0.001**1.711.43--2.06**\<0.001**1.861.58--2.56**\<0.001**1.601.31--1.96**\<0.001** N23.282.79--3.85**\<0.001**2.432.02--2.92**\<0.001**2.542.11--3.05**\<0.001**2.101.71--2.58**\<0.001** N3a4.824.06--5.74**\<0.001**3.652.97--4.48**\<0.001**4.183.46--5.05**\<0.001**3.262.59--4.10**\<0.001** N3b8.998.99--7.10**\<0.001**6.384.74--8.59**\<0.001**5.023.65--6.90**\<0.001**4.813.27--7.09**\<0.001**Adjuvant therapy NoneRef--**--**Ref--**--**Ref--**--**Ref--**--** Chemotherapy0.710.62--0.81**\<0.001**0.670.56--0.79**\<0.001**0.530.35--0.82**0.005**0.730.43--1.230.241 Chemoradiotherapy0.940.77--1.160.5750.700.56--0.88**0.002**0.940.57--1.570.8250.430.24--0.78**0.005**Bold values indicate significance (*p* \< 0.05)*HR* hazard ratio, *CI* confidence interval, *NA* not applicable Fig. 1Adjusted survival curves from the proportional hazards model of the 5-year overall survival of **a** young patients (\<75 years) and **b** elderly patients (≥75 years), stratified for lymph node yield (\<15 nodes, 15--25 nodes and \>25 nodes). *Cum* Cumulative

Discussion {#Sec13}
==========

This population-based observational cohort study aimed to evaluate the influence of LNY on postoperative mortality and overall survival in patients aged 75 years or older who underwent curative gastrectomy for cancer. The results indicate that a high LNY improves survival for both young and elderly patients. In addition, LNY was not associated with postoperative mortality in these patients.

The findings of the present study are in line with several large population-based studies investigating the effect of LNY on survival.[@CR15],[@CR16] One of these studies found a linear trend for improved survival based on more harvested nodes, up to a cut-off point of 40 lymph nodes.[@CR15] Moreover, other studies demonstrated that in patients with a low LNY, no adequate prediction of patient survival could be made, suggesting inadequate staging.[@CR17],[@CR18] International and national guidelines therefore require examination of ≥15 lymph nodes for adequate staging of gastric cancer.[@CR9],[@CR14]

As elderly form a substantial portion of gastric cancer patients[@CR9] and are prone to postoperative morbidity and mortality,[@CR6] the extent of lymphadenectomy in elderly patients with gastric cancer has been under debate. Recently, a French study did not find a difference in survival between a high, low, and intermediate LNY in patients aged 75 years and older who underwent curative gastrectomy for cancer.[@CR10] Even though a higher LNY did not affect postoperative morbidity and mortality, the authors advise a limited lymphadenectomy due to the lack of a survival benefit. However, the effect of LNY on the outcomes was assessed in univariable analysis only, which does not allow for correction of well-known confounders such as patient and tumor characteristics. Such confounders may introduce bias, which is a challenging problem in retrospective observational studies.[@CR19] These limitations, as well as the possible implications of the authors' recommendations on daily practice, made evaluation of these findings warranted. The present study has taken these limitations into account by including almost four times as many elderly patients from a more recent cohort, and by performing a multivariable analysis. The current results confirm the absence of increased postoperative mortality, but support the oncological value of an extensive lymphadenectomy in all patients undergoing curative gastrectomy for cancer with a clear survival benefit.

The present study chose a cut-off point of 75 years to be able to make a fair comparison with the French study; however, the definition of 'elderly' is arbitrary and we do not believe that age should be a 'hard-stop' discriminator for the choice of the extent of treatment. In our opinion, patient fitness rather than age should be considered when choosing the appropriate treatment. For patient fitness, factors such as comorbidities, smoking status, and weight loss should be taken into account.[@CR20]

Interestingly, LNY increased over the years, especially in the last period (2012--2014). In The Netherlands, a D2 lymphadenectomy has been standard of care since the final publication of the Dutch D1--D2 trial;[@CR21] therefore, a D2 lymphadenectomy was recommended throughout the whole study period. It could be that surgical quality increased over the years due to centralization of stomach surgery in The Netherlands (started in 2009), but no data are currently available to support this hypothesis. Another factor is the start of the Dutch Upper GI Cancer Audit (DUCA) in 2011, which has contributed to an increase in LNY.[@CR22] In the DUCA, LNY (\>15 nodes) is seen as an important quality indicator, which may have motivated centers to increase their LNY.[@CR22] This increase may then be due to an improvement in surgical quality, but could also be attributed to a more thorough inspection of the resection specimen by pathologists.

It is important to realize that LNY does not fully correspond to the extent of lymphadenectomy. Although a D2 lymphadenectomy is recommended by national and international guidelines,[@CR11],[@CR23] the Dutch D1--D2 trial demonstrated that more than half of the resection specimens, which were indicated to have had a D2 lymphadenectomy, lacked two or more of the required lymph node stations.[@CR24] On the other hand, one-quarter of these resection specimens included more than the intended lymph nodes stations. These results indicate that both the French study and the current study do not know exactly which lymphadenectomy was actually performed by the surgeons. In addition to these uncertainties, there might be variation in lymphadenectomy between surgeons, variation in the submission of specimens (*en bloc* or in separate containers),[@CR25] and variation in lymph node retrieval by pathologists,[@CR26] all of which may influence the final LNY. All these factors combined imply that caution should be taken in drawing conclusions on the extent of lymphadenectomy, based solely on counting lymph nodes. In addition, the applicability of LNY as a surrogate for lymphadenectomy without data on tumor recurrence should be carefully interpreted. Ideally, a randomized controlled trial comparing different types of lymphadenectomies in elderly patients should be performed in order to provide a fair answer to this topic. On the other hand, such a study might not be considered ethical regarding the favorable results of an extensive lymphadenectomy,[@CR7],[@CR27] especially since postoperative mortality seems not to be increased as a result of the lymphadenectomy.

Although the present study corrected for many confounding factors, including patient and tumor characteristics, data on patients' comorbidities, American Society of Anesthesiologists (ASA) status, body mass index (BMI), and disease recurrence were not available from the NCR database. Therefore, we could not correct for these well-known patient confounders, which could have influenced the extent of lymphadenectomy performed (selection bias), nor could we investigate the influence of LNY on disease-free survival. For instance, patients with poor performance status or severe comorbidities might have undergone a less extended lymphadenectomy. Moreover, NCR data lack information on the type of chemotherapy and the number of cycles, and administration of palliative chemotherapy is absent. Palliative chemotherapy has been shown to improve survival compared with supportive care.[@CR28] As a large number of patients develop distant metastases, the use of systemic therapy may influence survival. Furthermore, no data on hospital volume were available, which may influence both LNY and postoperative outcomes. Lastly, there might be some unknown confounding due to the retrospective nature of the study.

Conclusion {#Sec14}
==========

A high LNY is associated with prolonged survival but not with an increase in postoperative mortality, for young as well as elderly patients. Therefore, an extensive lymphadenectomy cannot be abandoned as the preferred strategy and should be considered in all patients during gastrectomy.
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